| Primary |
| Schizophrenia |
25.0% |
| Blood Sodium Decreased |
12.5% |
| Depression |
12.5% |
| Hypokalaemia |
12.5% |
| Ill-defined Disorder |
12.5% |
| Insomnia |
12.5% |
| Psychotic Disorder |
12.5% |
|
| Loss Of Consciousness |
20.0% |
| Neuroleptic Malignant Syndrome |
20.0% |
| Parkinsonism |
20.0% |
| Pleurothotonus |
20.0% |
| Weight Increased |
20.0% |
|
| Secondary |
| Product Used For Unknown Indication |
54.1% |
| Drug Use For Unknown Indication |
10.2% |
| Schizophrenia |
9.4% |
| Psychotic Disorder |
5.8% |
| Depression |
2.5% |
| Schizophrenia, Paranoid Type |
2.2% |
| Schizoaffective Disorder |
1.8% |
| Bipolar I Disorder |
1.7% |
| Anxiety |
1.6% |
| Bipolar Disorder |
1.5% |
| Schizophrenia, Catatonic Type |
1.3% |
| Ill-defined Disorder |
1.1% |
| Diabetes Mellitus |
1.1% |
| Insomnia |
1.1% |
| Abnormal Behaviour |
0.9% |
| Brain Injury |
0.9% |
| Hypertension |
0.9% |
| Schizophrenia, Disorganised Type |
0.9% |
| Autism |
0.7% |
| Mental Disorder |
0.7% |
|
| Pericarditis |
15.5% |
| Urinary Retention |
12.6% |
| Galactorrhoea |
6.9% |
| Neuroleptic Malignant Syndrome |
5.7% |
| Pleurothotonus |
5.2% |
| Restlessness |
5.2% |
| Sudden Death |
5.2% |
| Tachycardia |
4.6% |
| Vomiting |
4.6% |
| Weight Increased |
4.0% |
| Drug Toxicity |
3.4% |
| Parkinsonism |
3.4% |
| Schizophrenia |
3.4% |
| White Blood Cell Count Increased |
3.4% |
| Extrapyramidal Disorder |
2.9% |
| Hypoglycaemia |
2.9% |
| Long Qt Syndrome |
2.9% |
| Sepsis |
2.9% |
| Somnolence |
2.9% |
| Agitation |
2.3% |
|
| Concomitant |
| Schizophrenia |
18.9% |
| Product Used For Unknown Indication |
16.2% |
| Depression |
9.7% |
| Psychotic Disorder |
8.8% |
| Drug Use For Unknown Indication |
7.5% |
| Prophylaxis |
5.2% |
| Hypertension |
3.8% |
| Bipolar Disorder |
3.5% |
| Hepatitis C |
3.2% |
| Sedation |
3.2% |
| Schizophrenia, Paranoid Type |
2.5% |
| Pruritus |
2.4% |
| Anxiety |
2.3% |
| Insomnia |
2.2% |
| Sleep Disorder |
2.2% |
| Acute Myeloid Leukaemia |
1.9% |
| Affective Disorder |
1.8% |
| Mania |
1.8% |
| Antidepressant Therapy |
1.4% |
| Chronic Hepatitis C |
1.4% |
|
| Weight Increased |
10.4% |
| Neutropenia |
8.2% |
| Type 2 Diabetes Mellitus |
7.7% |
| Thrombocytopenia |
7.1% |
| Schizophrenia |
6.6% |
| Vomiting |
6.0% |
| Somnolence |
5.5% |
| Thyroxine Increased |
4.9% |
| Death |
4.4% |
| Obsessive-compulsive Disorder |
4.4% |
| Suicidal Ideation |
4.4% |
| Psychotic Disorder |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Overdose |
3.3% |
| Porphyria Non-acute |
3.3% |
| Rhabdomyolysis |
3.3% |
| Sedation |
3.3% |
| Tardive Dyskinesia |
3.3% |
| Tremor |
3.3% |
| Weight Decreased |
3.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
38.7% |
| Product Used For Unknown Indication |
21.0% |
| Atrial Fibrillation |
6.5% |
| Psychotic Disorder |
4.8% |
| Depression |
3.2% |
| Mental Disorder |
3.2% |
| Parkinson's Disease |
3.2% |
| Schizophrenia, Paranoid Type |
3.2% |
| Smoking Cessation Therapy |
3.2% |
| Aggression |
1.6% |
| Agitation |
1.6% |
| Alcohol Use |
1.6% |
| Essential Hypertension |
1.6% |
| Hyperlipidaemia |
1.6% |
| Prophylaxis |
1.6% |
| Schizophrenia |
1.6% |
| Schizotypal Personality Disorder |
1.6% |
|
| Tardive Dyskinesia |
18.8% |
| Drug Interaction |
15.6% |
| Parkinsonism |
9.4% |
| Neuroleptic Malignant Syndrome |
6.3% |
| Rhabdomyolysis |
6.3% |
| Shock |
6.3% |
| Somnolence |
6.3% |
| Weight Increased |
6.3% |
| Atrial Fibrillation |
3.1% |
| Enuresis |
3.1% |
| Grand Mal Convulsion |
3.1% |
| Hyponatraemia |
3.1% |
| Ileus Paralytic |
3.1% |
| Overdose |
3.1% |
| Psychotic Disorder |
3.1% |
| Sinus Arrest |
3.1% |
|
